1h Free Analyst Time
Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 3, 3 and 2 respectively.
Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Oncology and Women's Health which include indications Obesity, Anorexia Nervosa, Cachexia, Cancer Anorexia-Cachexia Syndrome, Female Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, IgA Nephropathy (Berger's Disease), Metabolic Syndrome, Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome) and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
- The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanocortin Receptor 4 (MC4R)+ targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Melanocortin Receptor 4 (MC4R) - Overview
- Melanocortin Receptor 4 (MC4R) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
- Endevica Bio
- LG Chem Ltd
- Mallinckrodt Plc
- Palatin Technologies Inc
- Pfizer Inc
- Rhythm Pharmaceuticals Inc
- Melanocortin Receptor 4 (MC4R) - Drug Profiles
- bremelanotide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- corticotropin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LB-54640 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PF-07258669 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PL-8905 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PL-9610 - Drug Profile
- Product Description
- Mechanism Of Action
- setmelanotide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- setmelanotide hydrochloride ER - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Agonize MC4-R for Obesity - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
- Product Description
- Mechanism Of Action
- TCMCB-07 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Melanocortin Receptor 4 (MC4R) - Dormant Products
- Melanocortin Receptor 4 (MC4R) - Discontinued Products
- Melanocortin Receptor 4 (MC4R) - Product Development Milestones
- Featured News & Press Releases
- Jul 26, 2022: Palatin announces preliminary fourth quarter Vyleesi net product revenue increased 225% over prior quarter
- Jul 22, 2022: Rhythm Pharmaceuticals receives positive CHMP opinion for IMCIVREE(setmelanotide) for the treatment of obesity and control of hunger in patients with Bardet-Biedl Syndrome
- Jul 20, 2022: Rhythm pharmaceuticals announces early access authorization for setmelanotide for use in patients with Bardet-Biedl syndrome in France
- Jul 20, 2022: Rhythm Pharmaceuticals announces early access authorization for setmelanotide for use in patients with Bardet-Biedl Syndrome in France
- Jul 18, 2022: NICE recommends Rhythm’s IMCIVREE (setmelanotide) for treating obesity and controlling hunger caused by POMC or LEPR Deficiency
- Jul 13, 2022: Endevica Bio doses first patient in phase 1 clinical trial of TCMCB07 for the treatment of cachexia
- Jul 12, 2022: Rhythm Pharmaceuticals announces positive interim results from phase 2 clinical trial evaluating setmelanotide in hypothalamic obesity
- Jun 28, 2022: Endevica reports the U.S. FDA accepted its Investigational New Drug (IND) Application for TCMCB07, a Melanocortin-4 Antagonist Peptide
- Jun 22, 2022: Rhythm Pharmaceuticals launches IMCIVREE (setmelanotide) in Germany for the treatment of obesity and control of hunger associated with POMC or LEPR deficiency
- Jun 22, 2022: Rhythm Pharmaceuticals announces that European Commission authorized variation for IMCIVREE (setmelanotide) to allow for dosing in patients with POMC or LEPR deficiency with renal impairment
- Jun 16, 2022: LG Chem’s new drug for obesity receives additional orphan drug designation by the US FDA
- Jun 16, 2022: Rhythm Pharmaceuticals announces FDA approval of IMCIVREE (setmelanotide) for use in patients with Bardet-Biedl Syndrome
- Jun 13, 2022: Rhythm Pharmaceuticals presents new data from long-term extension trial evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR deficiency obesity at ENDO 2022
- May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference
- May 02, 2022: Rhythm Pharmaceuticals presents new data from phase 3 trial evaluating setmelanotide in patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Endevica Bio, 2022
- Pipeline by LG Chem Ltd, 2022
- Pipeline by Mallinckrodt Plc, 2022
- Pipeline by Palatin Technologies Inc, 2022
- Pipeline by Pfizer Inc, 2022
- Pipeline by Rhythm Pharmaceuticals Inc, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Endevica Bio
- LG Chem Ltd
- Mallinckrodt Plc
- Palatin Technologies Inc
- Pfizer Inc
- Rhythm Pharmaceuticals Inc
